Does losing weight by taking GLP-1 drugs such as Ozempic and Wegovy actually improve your risk of other diseases associated with obesity? New research led by scientists at the University of Liverpool in the UK, and presented at the European Congress on Obesity (ECO 2026), could have an answer.

As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.

Does losing weight by taking GLP-1 drugs such as Ozempic and Wegovy actually improve your risk of other diseases associated with obesity? New research led by scientists at the…

Scientists are looking to see how GLP-1 drugs may impact the brain and reshape people’s nervous systems

NOVA studija pokazuje da je smanjenje rizika od bolesti povezanih s pretilošću izravno vezano uz količinu kilograma izgubljenih pomoću GLP-1 lijekova poput Ozempica.

A recent trial is the latest to suggest that GLP-1s aren't just for treating diabetes and obesity.

A Liverpooli Egyetem kutatói 89 718 amerikai egészségügyi adatait vizsgálva derítette ki, milyen hosszútávú hatása lehet a fogyást segítő csodaszereknek.

New-generation GLP-1 drugs, such as retatrutide, are achieving higher rates of weight loss. How much weight is too much and too fast to lose?

GLP-1 drugs may curb addiction and craving, making some patients less likely to drink alcohol. It could ease anxiety, compulsive thinking and emotional distress | World News